Sarepta Therapeutics (SRPT) Share-based Compensation (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Share-based Compensation of -$109.1 million for Q4 2025, down 319.48% year-over-year from $49.7 million in Q4 2024, and down 765.29% quarter-over-quarter from $16.4 million in Q3 2025.
Sarepta Therapeutics (SRPT) Share-based Compensation (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Share-based Compensation history runs 16 years deep, the most recent figure standing at -$109.1 million for Q4 2025.
- In Q4 2025, Share-based Compensation fell 319.48% year-over-year to -$109.1 million; the TTM figure through Mar 2026 stood at -$51.1 million (down 148.62% YoY), while the FY2025 annual figure was $218.0 million, down 8.6% from the prior year.
- Share-based Compensation for Q4 2025 stood at -$109.1 million, down from $16.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $102.9 million in Q2 2022, with the low at -$109.1 million in Q4 2025.
- The 5-year median for Share-based Compensation is $41.4 million (2023), against an average of $26.4 million.
- Peak annual rise in Share-based Compensation reached 395.64% in 2025, while the deepest fall reached 319.48% in 2025.
- Sarepta Therapeutics' Share-based Compensation stood at -$70.9 million in 2021, then surged by 171.21% to $50.5 million in 2022, then retreated by 9.3% to $45.8 million in 2023, then gained by 8.48% to $49.7 million in 2024, then tumbled by 319.48% to -$109.1 million in 2025.
- Business Quant data shows SRPT's Share-based Compensation at -$109.1 million in Q4 2025, $16.4 million in Q3 2025, and $41.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 28.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.03 Mn |
| Jun 30, 2026 | 28.03 Mn |
| Mar 31, 2026 | 33.67 Mn |
| Mar 31, 2026 | 33.67 Mn |
| Dec 31, 2025 | -109.08 Mn |
| Dec 31, 2025 | -109.08 Mn |
| Sep 30, 2025 | 16.40 Mn |
| Sep 30, 2025 | 16.40 Mn |
| Jun 30, 2025 | 41.62 Mn |
| Jun 30, 2025 | 41.62 Mn |
| Mar 31, 2025 | 5.23 Mn |
| Mar 31, 2025 | 5.23 Mn |
| Dec 31, 2024 | 49.70 Mn |
| Dec 31, 2024 | 49.70 Mn |
| Sep 30, 2024 | -5.55 Mn |
| Sep 30, 2024 | -5.55 Mn |
| Jun 30, 2024 | 55.65 Mn |
| Jun 30, 2024 | 55.65 Mn |
| Mar 31, 2024 | 45.21 Mn |
| Mar 31, 2024 | 45.21 Mn |